



Interventional Therapies for Migraine



Wade M. Cooper, DO

Director,
Headache and Neuropathic Pain Program
University of Michigan
Ann Arbor, Michigan

Learning Objective

Upon completion of this activity, participants should be able to

- Describe new advances in the pathophysiology of migraine
- Develop treatment plans in line with standards of practice for preventive management of migraine

Launch Date: January 31, 2019

Expires On: January 31, 2021

How to Claim Credit

There are no fees for viewing the CME content or receiving credit for this activity. After completion of the activity, click on the link to 'Claim Credit.' You will be taken to MedEd Manager to complete the evaluation and outcome question surveys.

You may be prompted to log in to MedEd Manager or create a profile. The profile is free of charge.

You will receive a follow-up evaluation 3 months after the date you claimed your credit.

Target Audience

The target audience for this activity includes primary care physicians, specialists, and other clinicians who have an interest in migraine and other headache disorders, including pharmacists, physician assistants, nurse practitioners, and nurses.

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Forefront Collaborative and the Diamond Headache Clinic Research & Educational Foundation.



Accreditation Statement (cont.)

Forefront Collaborative is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation Statement

Forefront Collaborative designates this enduring material for a maximum of 0.25 *AMA PRA Category 1 Credit™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure and Conflict of Interest Resolution

Educational activities provided by Forefront Collaborative must demonstrate balance, independence, and scientific rigor. All those in a position to control the content of an activity must disclose all relevant financial relationship(s) with commercial interest(s)*. For this educational activity, all conflicts of interest have been resolved through peer review and revisions to ensure independence, evidence base, fair balance, and absence of commercial bias. Disclosures appear below.

The ACCME defines a **commercial interest as any entity producing, marketing, reselling, or distributing healthcare goods or services consumed by or used on patients. The ACCME does not consider providers of clinical service directly to patients to be commercial interests.*

The following individuals have indicated that neither they nor their spouses/partners have had, in the past 12 months, financial relationship(s) with commercial interests relative to the content of this CME activity:

Planners

- Christine Tebben (Forefront Collaborative)
- Patient

The following individuals have disclosed that they and/or their spouse/partner has had a financial relationship in the past 12 months:

Faculty

- Wade M. Cooper, DO: consultant for Alder, Amgen, Dolor Technologies, Lilly, and Teva; advisory board for Alder, Amgen, Lilly, Promius, and Teva; ownership interest in Dolor Technologies

Planners (Diamond Headache Clinic Research and Educational Foundation)

- Merle L. Diamond, MD: consultant for Alder, Amgen, Lilly, Novartis, Promius, Teva; speaker's bureau for Amgen, Avanir, Depomed, Lilly, Novartis, Supernus, Teva; advisory board for Alder, Amgen, Avanir, Depomed, Lilly, Novartis, Promius, Supernus, Teva, and Upsher-Smith
- Konrad Kothmann: consultant for Amgen, Lilly, and Novartis

Planner (Forefront Collaborative)

- Lily Zurkovsky, PhD: personal stock in Teva Pharmaceutical Industries Ltd.

CME Content Review

The content of this activity was independently peer reviewed. The reviewers of this activity have no relevant financial relationships to disclose.

This continuing medical education activity may include reference(s) to unlabeled or unapproved uses of drugs or devices.



DIAMOND HEADACHE CLINIC
RESEARCH & EDUCATIONAL
FOUNDATION

Disclaimer

The views and opinions expressed in this activity are those of the faculty and do not necessarily reflect the views or recommendations of Forefront Collaborative.

Commercial Support

This activity is supported by educational funding donation provided by Amgen.